Swedish Orphan Biovitrum AB (Sobi), has entered into a deal to acquire the rights to AstraZeneca’s Synagis (palivizumab) in the U.S. for $1.5 billion upfront, which includes $1 billion in cash and $500 million in Sobi shares. In addition, deferred and contingent payments depending on certain conditions may be payable. Also as part of the deal, Sobi will lay claim to 50 percent of the future earnings of the candidate drug MEDI8897 in the U.S.   The deal diversifies Sobi’s revenue base in specia...